Neurological Sciences

, Volume 40, Issue 2, pp 385–391 | Cite as

Relationship between thiol-disulphide homeostasis and visual evoked potentials in patients with multiple sclerosis

  • Gönül VuralEmail author
  • Şadiye Gümüşyayla
  • Orhan Deniz
  • Salim Neşelioğlu
  • Özcan Erel
Original Article



To examine the thiol-disulphide homeostasis during an optic neuritis episode in patients with multiple sclerosis and the relationship between this homeostasis and P100 wave latency.

Materials and method

Visual evoked potential reviews of multiple sclerosis patients who presented with an optic neuritis episode were conducted and P100 latencies were measured. Peripheral blood samples were collected from all patients. Native thiol and total thiol concentrations were measured with the automated method that was recently developed. Their amount of disulphide bonds, disulphide/native thiol, disulphide/total thiol and native thiol/total thiol ratios were calculated. The relationship between P100 latency and thiol-disulphide homeostasis was investigated.


A significant positive correlation was determined between the disulphide/native thiol ratio and both mean P100 latency and maximum P100 latency (p = 0.021, r = 0.136; p = 0.030, r = 0.177, respectively).


As the balance of the plasma dominated by antioxidants moves towards the oxidant side, in other words as a higher rate of thiol is oxidised from the thiol pool, P100 latency is extended. N-acetylcysteine and alpha lipoic acid as well as thiol supplements can improve the thiol-disulphide balance, reinforce antioxidant defence and it can help in slowing down the demyelinating damage.


Multiple sclerosis Optic neuritis Thiol-disulphide homeostasis Oxidative stress Visual evoked potential 



The biochemical analysis of the study was performed at the biochemistry lab of Ataturk Education and Research Hospital. The authors would like to express their thanks to the staff of the biochemistry lab and Özcan Erel’s research assistants for the invaluable assistance, as well as MAT Statistical Analysis Service that conducted the statistical analysis of the study.

Compliance with ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

The authors declare that they have no conflicts of interest.


  1. 1.
    Tully M, Shi R (2013) New insights in the pathogenesis of multiple sclerosis—role of acrolein in neuronal and myelin damage. Int J Mol Sci 14:20037–20047PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Ortiz GG, Pacheco-Moises FP, Bitzer-Quintero OK, Ramírez-Anguiano AC, Flores-Alvarado LJ, Ramírez-Ramírez V, Macias-Islas MA, Torres-Sánchez ED (2013) Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. Clin Dev Immunol 2013:1–14CrossRefGoogle Scholar
  3. 3.
    Francis GS, Duquette P, Antel JP (1996) Inflammatory demyelinating diseases of the central nervous system. In: Bradley WG, Daroff RB, Fenickel GM, Marsden CD (eds) Neurology in clinical practice, 2nd edn. Butterworth-Heinemann, Boston, pp 1307–1343Google Scholar
  4. 4.
    Kale N (2016) Optic neuritis as an early sign of multiple sclerosis. Eye Brain 26(8):195–202CrossRefGoogle Scholar
  5. 5.
    Apple DJ, Rabb MF (1991) Ocular pathology, 4th edn. Mosby Year Book, St. LouisGoogle Scholar
  6. 6.
    Ortiz GG, Macias-Islas MA, Pacheco-Moises FP, Cruz-Ramos JA, Sustersik S, Barba EA, Aguayo A (2009) Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 26:35–39PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Erel O, Neselioglu S (2014) A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 47:326–332PubMedCrossRefGoogle Scholar
  8. 8.
    Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749–762PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Biswas S, Chida AS, Rahman I (2006) Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem Pharmacol 71:551–564PubMedCrossRefGoogle Scholar
  10. 10.
    Tassed I, Agüera E, Sanchez-Lopez F, Feijóo M, Giraldo AI, Cruz AH, Gascón F, Túnez I (2012) Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 45:440–444CrossRefGoogle Scholar
  11. 11.
    Compston A, Coles A (2008) Multiple sclerosis. Lancet 372:1502–1517PubMedCrossRefGoogle Scholar
  12. 12.
    Witherick J, Wilkins A, Scolding N, Kemp K (2011) Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment. Autoimmune Dis 2011:164608Google Scholar
  13. 13.
    vanHorssen J, Witte ME, Schreibelt G, de Vries HE (2011) Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 1812:141–150CrossRefGoogle Scholar
  14. 14.
    Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schininà ME, DiDomenico F, De Marco F, Perluigi M (2013) Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis. PLoS One 8(6):e65184PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Gonsette RE (2008) Neurodegeneration in multiplesclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 274(1):48–53PubMedCrossRefGoogle Scholar
  16. 16.
    Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I (2012) Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem 45(1–2):26–30PubMedCrossRefGoogle Scholar
  17. 17.
    Karlik M, Valokovic P, Hancinova V, Krizova L, Tothova L, Celec P (2015) Markers of oxidative stress in plasma and saliva in patients with multiple sclerosis. Clin Biochem 48:24–28PubMedCrossRefGoogle Scholar
  18. 18.
    Usatyuk PV, Natarajan V (2012) Hydroxy alkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc Res 83(1):45–55PubMedCrossRefGoogle Scholar
  19. 19.
    Lassman H, van Horssen J (2011) The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett 585:3715–3723CrossRefGoogle Scholar
  20. 20.
    Ansari MA, Roberts KN, Scheff SW (2008) Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury. Free Radic Biol Med 45:443–452PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Miller E, Mrowicka M, Saluk-Juszczak J, Ireneusz M (2011) The level of isoprostanes as a non-invasive marker for in vivo lipid peroxidation in secondary progressive multiple sclerosis. Neurochem Res 36(6):1012–1016PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Beckman JS, Koppenol WH (1996) Nitricoxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Phys 271:1424–1437CrossRefGoogle Scholar
  23. 23.
    Friese MA, Schattling B, Fugger L (2014) Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. Nat Rev Neurol 10(4):225–238PubMedCrossRefGoogle Scholar
  24. 24.
    Koch M, Mostert J, Arutjunyan AV, Stepanov M, Teelken A, Heersema D, De Keyser J (2007) Plasma lipid peroxidation and progression of disability in multiple sclerosis. Eur J Neurol 14:529–533PubMedCrossRefGoogle Scholar
  25. 25.
    Besler HT, Comoğlu S, Okçu Z (2002) Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci 5:215–220PubMedCrossRefGoogle Scholar
  26. 26.
    Besler HT, Comoğlu S (2003) Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci 6:189–196PubMedCrossRefGoogle Scholar
  27. 27.
    Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, De Keyser J (2006) Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 253:483–487PubMedCrossRefGoogle Scholar
  28. 28.
    Syburra C, Passi S (1999) Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 71:112–115Google Scholar
  29. 29.
    Ferretti G, Bacchetti T, Principi F, DiLudovico F, Viti B, Angeleri VA, Danni M, Provinciali L (2005) Increased levels of lipid hydroperoxides in plasma of patients with multiple sclerosis: a relationship with paraoxonase activity. MultScler 11:677–682Google Scholar
  30. 30.
    Miller E, Mrowicka M, Malinowska K, Zolynski K, Kedziora J (2010) Effects of the whole-body cryotherapy on a total antioxidative status and activities of some antioxidative enzymes in blood of patients with multiple sclerosis-preliminary study. J Med Investig 57:168–173CrossRefGoogle Scholar
  31. 31.
    Oliveira SR, Kallaur AP, Simão AN, Morimoto HK, Lopes J, Panis C, Petenucci DL, da Silva E, Cecchini R, Kaimen-Maciel DR, Reiche EM (2012) Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 321(1–2):49–53PubMedCrossRefGoogle Scholar
  32. 32.
    Ljubisavljevic S, Stojanovic I, Vojinovic S, Stojanov D, Stojanovic S, Cvetkovic T, Savic D, Pavlovic D (2013) The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in plasma and CSF. Neurochem Int 62(7):988–997PubMedCrossRefGoogle Scholar
  33. 33.
    Pasquali L, Pecori C, Lucchesi C, LoGerfo A, Iudice A, Siciliano G, Bonuccelli U (2015) Plasmatic oxidative stress biomarkers in multiple sclerosis: relation with clinical and demographic characteristics. Clin Biochem 48:19–23PubMedCrossRefGoogle Scholar
  34. 34.
    Mirshafiey A (2007) Venom therapy in multiple sclerosis. Neuropharmacology 53:353–361PubMedCrossRefGoogle Scholar
  35. 35.
    Calabrese V, Bella R, Testa D, Spadaro F, Scrofani A, Rizza V, Pennisi G (1998) Increased cerebrospinal fluid and plasma levels of ultra weak chemiluminescence are associated with changes in the thiol pool and lipid soluble fluorescence in MS: the pathogenic role of oxidative stress. Drugs Exp Clin Res 24:125–131PubMedGoogle Scholar
  36. 36.
    Fuhr P, Kappos L (2001) Evoked potentials for evaluation of multiple sclerosis. Clin Neurophysiol 112:2185–2189PubMedCrossRefGoogle Scholar
  37. 37.
    Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018) Multiple sclerosis. Lancet 391:1622–1636PubMedCrossRefGoogle Scholar
  38. 38.
    Dietrich M, Helling N, Hilla A, Heskamp A, Issberner A, Hildebrandt T, Kohne Z, Küry P, Berndt C, Aktas O, Fischer D, Hartung HP, Albrecht P (2018) Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental auto immune encephalomyelitis-optic neuritis model. J Neuroinflammation 15(71):1–13Google Scholar
  39. 39.
    Vural G, Gumusyayla S, Bektas H, Deniz O, Ergin M, Erel O (2016) Dynamic thiol-disulphide homeostasis in patients with multiple sclerosis. WJNS 6:214–219CrossRefGoogle Scholar
  40. 40.
    Adamczyk B, Niedziela N, Adamczyk-Sowa M (2017) Novel approaches of oxidative stress mechanisms in the multiple sclerosis pathophysiology and therapy. In: Zagon IS, McLaughlin PJ (eds) Multiple sclerosis: perspectives in treatment and pathogenesis. Codon Publications, Brisbane, pp 155–172CrossRefGoogle Scholar
  41. 41.
    Elmas B, Erel Ö, Ersavaş D, Yürümez Y (2017) Thiol/disulfide homeostasis as a novel indicator of oxidative stress in children with simple febrile seizures. Neurol Sci 38(11):1969–1975PubMedCrossRefGoogle Scholar
  42. 42.
    Kurt ANC, Aydın A, Demir H, Erel Ö (2017) Headache in children and dynamic thiol/disulfide balance evaluation with a new method. Neurol Sci 38(8):1495–1499PubMedCrossRefGoogle Scholar
  43. 43.
    Vural G, Bektas H, Gumusyayla S, Deniz O, Alışık M, Erel O (2018) Impaired thiol-disulphide homeostasis in patients with axonal polyneuropathy. Neurol Res 40(3):166–172PubMedCrossRefGoogle Scholar
  44. 44.
    Gumusyayla S, Vural G, Bektas H, Neselioglu S, Deniz O, Erel O (2016) A novel oxidative stress marker in migraine patients: dynamic thiol-disulphide homeostasis. Neurol Sci 37(8):1311–1317PubMedCrossRefGoogle Scholar
  45. 45.
    Vural G, Gumusyayla S, Bektas H, Deniz O, Alışık M, Erel O (2017) Impairment of dynamic thiol-disulphide homeostasis in patients with idiopathic Parkinson’s disease and its relationship with clinical stage of disease. Clin Neurol Neurosurg 153:50–55PubMedCrossRefGoogle Scholar

Copyright information

© Fondazione Società Italiana di Neurologia 2018

Authors and Affiliations

  1. 1.Department of Neurology, Faculty of MedicineYıldırım Beyazıt UniversityAnkaraTurkey
  2. 2.Department of Clinical Biochemistry, Faculty of MedicineYıldırım Beyazıt UniversityAnkaraTurkey

Personalised recommendations